MAIA Biotechnology, Inc. — Q3 2023 Form 10-Q
Reporting period: Three and nine months ended September 30, 2023; filed November 7, 2023. MAIA is a clinical-stage oncology biotechnology company developing THIO, with its lead program in advanced non-small cell lung cancer (NSCLC). The company reported no revenue.
Financial position and results
- Q3: Research and development expense was $2.60 million, general and administrative expense was $2.36 million, and net loss was $4.88 million, or $0.36 per share. No meaningful operating margin is available because the company has no revenue.
- Nine months: Operating expenses were $13.80 million and net loss was $13.52 million, or $1.08 per share. Net loss attributable to shareholders was 12% higher than in the prior-year period; reported net loss was 16% higher. The prior-year period included a $450,578 deemed dividend on warrant modification.
- Cash flow: Operating activities used $9.08 million in cash in the first nine months, compared with $9.15 million in 2022. Financing activities provided $4.25 million, primarily reflecting the 2023 follow-on offering net of costs. Cash declined by $4.85 million to $6.10 million.
- Liquidity and obligations: Working capital was approximately $2.48 million; current liabilities were $4.15 million. Total liabilities were $4.25 million. The balance sheet reports no conventional debt. Management states additional equity or debt financing will be needed and discloses substantial doubt about the company’s ability to continue as a going concern within one year after issuance of the statements.
- Equity: Stockholders’ equity fell to $2.75 million from $8.51 million at year-end 2022. Shares outstanding were 13.76 million at September 30 and 14,213,511 at November 7.
Changes versus the prior comparable period
- Q3 operating expenses declined 3% year over year, largely because the prior-year quarter included a one-time $1.10 million ratchet-share expense. Excluding that comparison, R&D rose 11% and G&A rose 43%.
- For the first nine months, operating expenses rose 15%: R&D increased 13%, mainly reflecting scientific research and development-related payroll, while G&A increased 48%, including public-company infrastructure, investor relations, insurance, payroll, and professional costs.
- Australian R&D incentive income was $149,457 for the nine months, down from $230,188. A $141,934 gain from remeasurement of warrant liabilities partly offset expenses.
Outlook, developments, and risks
- Management expects continued operating losses and negative operating cash flow as clinical trials progress. It says expense-control measures are in place but cannot assure that spending can be contained or additional financing raised on acceptable terms.
- The company reported positive topline safety lead-in results for THIO-101 in April 2023 and described preliminary survival and disease-control observations from a small number of patients. These are company-reported early clinical observations, not established evidence of efficacy.
- After quarter-end: FDA cleared the U.S. IND for THIO-101 on October 3, 2023. On October 10, MAIA reported 49 patients dosed in the trial. The filing does not provide a formal financial or revenue forecast.
- An at-the-market program permits up to $7 million of stock sales; no sales had occurred by September 30. By the filing date, MAIA reported selling 452,388 shares at an average $2.32, for approximately $1.05 million gross proceeds. Further sales may dilute shareholders.
- The board authorized repurchases of up to $800,000 through September 2024; none had occurred by September 30. The filing also warns repurchases could reduce cash available for operations or financing needs.
- MAIA terminated planned research activities in areas affected by the wars in Ukraine and Israel, citing uncertainty and potential adverse effects. It reported no material legal proceedings; UTSW license agreements include contingent milestone payments, none due as of September 30.
Key facts investors should verify
- Cash runway assumptions and the timing, amount, and terms of any additional financing, including subsequent ATM sales and potential dilution.
- Progress and independently assessable results from THIO-101, including the small patient samples underlying reported survival and disease-control observations.
- Whether the company proceeds with share repurchases despite disclosed funding needs and going-concern uncertainty.
- Follow-on offering proceeds: the filing presents differing net-proceeds figures in its narrative; reported financing cash flow for the nine months was $4.25 million.